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To my son, Pelle
“You cannot hope to build a better world without improving the individuals. 
To that end each of us must work for his own improvement and at the same 
time share a general responsibility for all humanity, our particular duty being 
to aid those to whom we think we can be most useful”. 
- Marie Curie 
 

  
ABSTRACT 
 
Selenium is an essential trace element, present in the 21st amino acid selenocysteine, 
which is specifically incorporated into selenoproteins. Today, there are 25 identified 
selenoproteins in humans, whereof many comprises redox active functions to uphold 
the intracellular redox balance. The redox activity is dependent on the location of 
selenocysteine within their active sites. It is also therefore selenium is recognized as an 
antioxidant.  
 
There are increasing number of studies with supporting evidences of redox active 
selenium compounds as anti-tumor metabolites, both in prevention and treatment of 
cancers, depending on the concentration. At lower doses selenium supplementation 
supports the synthesis and function of selenoproteins, while at higher concentration, 
selenium becomes a prooxidant and may cause reactive oxygen speices (ROS) 
formation, and induces cell death. Still, the selenium induced cytotoxic mechanisms in 
cancer are not fully characterized. The aim of this thesis was therefore undertaken to 
study the cytotoxic mechanism induced by some redox active selenium species in 
tumor cells, and their interaction with the thioredoxin and the glutaredoxin system. 
 
We found selenium compounds to be substrates of the glutaredoxin system, and that 
elevated Grx1 also increases the cytotoxicity of selenite, selenodiglutathione and 
seleno-DL-cystine. Moreover, selenite induced a redox shift within cells by increased 
cysteinylation and glutathionylation of proteins, which might be an important 
mechanism in selenium induced cytotoxicity. Methylselenol is considered to be the 
most reactive selenium metabolite to induce cell death in cancer cells. We showed the 
occurrence of a spontaneous methylation of selenide by s-adenosylmethionine (SAM) 
to form methylselenol. Methylselenol was a superior substrate for the thioredoxin and 
the glutaredoxin systems, compared to selenide. This newly formed selenium 
metabolite was also more toxic to tumor cells.  
 
Furthermore, selenite, selenodiglutathione and seleno-DL-cystine induce different 
programmed cell death (PCD) in HeLa cells, which was unexpected, since both selenite 
and selenodiglutathione are reduced to selenide. Selenodiglutathione was found to 
glutathionylate free protein thiols, which might be the reason to these diverse cell death 
mechanisms. Selenite induced a necroptosis-like cell death, while seleno-DL-cystine 
treatment induced two subgroups of cell death. One group was clearly apoptosis while 
the other displayed a paraptosis-like cell death, with massive cytoplasmic vacuolation 
and concomitant ER stress and unfolded protein response (UPR).  
 
In a study of selenite to promote all-trans retinoic acid (ATRA)-induced differentiation 
of acute promyelocytic leukemia (APL), we found selenite to potentiate the effect of 
ATRA induced maturation of NB4 cells. This was determined by increased expression 
of CD11b, nuclear morphology changes, and decrease of PML-RARα expression. This 
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differentiation might be redox regulated, since both selenite and ATRA induced 
changes of redox protein expression both on mRNA and protein level.  
 
In this thesis work, we show that selenium compounds are potent anti-tumoral drugs to 
induce cell death and to potentiate differentiation in leukemic cells. We conclude that 
the mechanisms are not only caused by ROS formation, but by multiple mechanisms, 
depending on molecular structure, which is of benefit to overcome drug resistance in 
tumors.  
 
 
  
Populärvetenskaplig sammanfattning 
 
Selen är ett essentiellt spårämne som finns i aminosyran selenocystein i selenproteiner. 
Det finns idag 25 identifierade humana selenproteiner, varav flera fungerar som 
antioxidanter i våra celler. Antioxidantfunktionen är beroende på var selenocysteinet är 
lokaliserat i selenproteinerna och skyddar då bland annat mot oxidativ stress och fria 
radikaler. I celler finns ett flertal enzymsystem som skyddar mot oxidativ stress, bland 
andra glutaredoxin- och tioredoxin systemen (som även innehåller selenproteinet 
tioredoxin reduktas (TrxR). 
Kroppen kan ta upp selen i olika former som sedan omvandlas genom flera kemiska 
reaktioner. Flertalet vetenskapliga studier har visat att redoxaktiva selenföreningar både 
kan förebygga och behandla tumörsjukdomar, beroende på vilken koncentration som 
ges. Selen är bra för kroppen i låga doser, men kan orsaka cellskada i höga doser. I låga 
doser hjälper selen till att upprätthålla lagom nivåerna av selenproteiner och dess 
funktioner, medan selen i högre doser fungerar som oxidanter och orsakar bildning av 
fria radikaler, speciellt i tumörceller eftersom dessa tar upp selen i mycket större mängd 
än vanliga celler. Det är dock ännu inte helt klarlagt hur selenet påverkar tumörceller, 
och vilka mekanismer som orsakar celldöd. 
 
Målet med den här avhandlingen var att studera de celldödsmekanismer som påverkas 
av olika selenföreningar vid behandling av tumörceller. Vi fann att selenföreningar är 
substrat (dvs. reagerar) för Glutaredoxin 1 (Grx1) och denna reaktion bidrar därmed till 
selen-metabolism i cellerna. Vi fann även att höga nivåer av Grx1 bidrog till en ökad 
celldöd vid behandling med selenföreningarna, och att selenit aktiverade 
försvarsmekanismer i cellerna som är till för att skydda proteiner mot oxidativ stress, 
men som även kan leda till förlust av funktioner hos vissa proteiner.  
 
Metylselenol är den selenförening som man tror är den mest aktiva varianten som 
orsakar celldöd i tumörceller. Vi fann att methylselenol kan bildas spontat då selenid 
reagerar med s-adenosylmetionin. Vi visade även att den var ett ännu bättre substrat för 
glutaredoxin- och tioredoxinsystemen, jämfört med andra selenföreningar. Denna 
spontant bildade metylselenolen inducerade också en ökad celldöd i tumörceller, 
jämfört med de övriga selenföreningar som studerades.  
 
I en fördjupad celldödsstudie fann vi att selenit, selenodiglutation och selenocystin 
inducerade olika typer av celldöd, via olika mekanismer, i de tumörceller som vi 
studerade. Dess fynd baserades på bland annat förändringar av morfologi (dvs. 
cellernas utseende i mikroskopet), genuttryck, proteinnivåer, aktivering av fria 
radikaler, energi-produktion och förmågan hos selen att binda till DNA och proteiner.  
I vidare studier har vi undersökt om selenit kunde förstärka effekten av den vanligen 
förekommande behandlingen av leukemi, ATRA, som är en form av A-vitamin. Vi 
fann att selenit ökade ATRA´s effekt att få leukemi cellerna att mogna ut (differentiera) 
till normalt fungerande blodceller och bromsa deras tillväxthastighet. Detta gjordes 
 4 
 
genom att undersöka speciella ytmarkörer, förändringar av geners uttryck, nivåer av 
speciella protein och cellkärnans form.  
 
Sammanfattningsvis har vi visat att selenföreningar har potential att användas vid 
behandling av tumörer och får leukemiceller att ändras till mer normalt fungerande 
blodceller (dvs. differentiera). Våra slutsatser är att dessa mekanismer inte enbart är 
orsakade av oxidativ stress och fria radikaler, utan också omfattar ett flertal 
intracellulära reaktioner samt beroende på den molekylstruktur som selenföreningar 
har. Detta är också till fördel för att undvika de resistensmenakismer som tumörceller 
ofta utvecklar vid behandling med konventionella cellgifter.  
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1 INTRODUCTION 
 
1.1 SELENIUM 
 
1.1.1 Background 
In 1817, the Swedish chemist, Jöns Jacob Berzelius, a part owner of a chemical factory 
at Gripsholm in Mariefred, discovered a new red element while purifying sulphur from 
iron pyrite delivered from the Falun copper mine in Falun [1]. Berzelius named this 
new, non-metal compound, selenium (named after the moon, Selene, σελήνη in Greek), 
which has similar chemical properties as sulphur. Selenium is present in group VI 
within the periodic table, with atomic number 34 and an atomic mass of 78.96. With 
five oxidation states (-2, 0, +2, +4 and +6), selenium can be constituents of many 
chemicals. 
 
The selenium content varies geographically around the world, depending on the 
mineral composition in the bedrock, geography and the leakage into the ground water. 
Even within the same continent, the soil selenium concentrations can vary greatly. 
Large areas of the Great Plain, USA, contain high-selenium soil, which makes some 
plants highly toxic to cattles [2]. Within growing plants, selenium is mainly found in 
organic forms, predominantly selenomethionine (SeMet), selenocysteine (SeCys) and 
selenomethylselenocysteine (SeMetCys). In contrast, selenate (SeO42-), and selenite 
(SeO32-), are the major selenium forms in the water and soil [3].  
 
1.1.2 Nutritional requirements, biological effects and toxicity 
 
According to the Swedish National Food Administration, the recommended daily 
intake of selenium is 50 µg for men, 40 µg for women and 55 µg during pregnancy and 
breast feeding. The soils selenium content is noticeably low in most areas of Europe, 
including Sweden. Good food sources of selenium are exemplified by Brazil nuts, 
beans and kidney, with moderate levels in liver, shellfish, fish, crops and eggs.  
 
Selenium deficiency has been related to several serious health conditions. Among these 
are cardiovascular diseases [4], immunodeficiency [5], thyroiditis [6], hyperthyroidism 
[7] stroke, dysfunction in reproduction [8], aging [9] and cancer [10-12]. In areas with 
low selenium containing soil (e.g., parts of China), incidences of Keshan disease have 
been reported. This disease affects the heart muscle of children and women in 
childbearing age, leading to an early death [13]. Although, lately it has been debated 
whether other underlying factors are involved [14]. Another disease related to selenium 
deficiency is Kashin-Beck disease, causing deformation of bones and osteoarthropathy 
[13, 15].The biological functions of selenium are mostly mediated by selenoproteins 
(table I), as exemplified by the thyroid hormone metabolism, redox reactions, male 
fertility and function of immune system among other effects [16]. However, the health 
benefit of selenium is strictly concentration dependent (figure 1). At moderate doses, 
selenium possess antioxidant capacity and stimulate cell growth, while selenium at high 
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doses becomes a strong oxidant and inhibits cell growth and may cause toxicity [17]. 
High selenium intake may cause selenosis, with toxic symptoms in the acute phase 
comprising garlic odor breath, nausea, vomiting, tachycardia, pulmonary and brain 
edema, which might be lethal [18]. There are also growing evidences of selenium in 
higher doses to function as an anticarcinogenic agent (thoroughly described in section 
1.3.4-1.3.5). 
 
 
Figure 1. The biological 
responses of selenium. 
The biological effect of 
selenium is strictly 
concentration dependent. 
Selenium deficiency may 
lead to diseases and 
death, as well as 
selenium in very high 
doses, due to acute 
toxicity. At moderate 
doses, selenium fulfills 
the requirements and 
possesses antioxidant 
properties and 
chemopreventive effects, 
while selenium in sub-toxic doses and above becomes a prooxidant, resulting in growth 
inhibition and anti-carcinogenic effects. 
 
1.1.3 Incorporation of selenium  
 
Selenium is present as a constituent of 21st aminoacid selenocysteine (SeCys) (analogue 
to cysteine), and crucial for the activity of several selenium containing proteins, when 
localized within their active sites. The specific incorporation of selenium into 
selenocysteine is an evolutionary conserved mechanism and unique. Selenocysteine is 
encoded by the UGA-codon, the same as for stop-signaling during translation, localized 
into the open reading frame (ORF) of the mRNA of selenoproteins. The Selenocysteine 
Insertion Sequence (SECIS) in mammals is present in the untranslated mRNA. 
Recruitment of a specific elongation factor (EFSec) by SECIS binding protein (SBP2), 
translates UGA as selenocysteine, instead of termination [19].  
 
Differently compared to other aminoacids, selenocysteine is synthesized on its specific 
tRNA (tRNA[Ser]Sec), recognizing serine as an intermediate, and unique since this 
regulates the expression and synthesis of all selenoproteins (Reviewed in [20]). 
Selenophophate syntethase SPS2, which is a selenoenzyme, phosphorylates selenide 
before formation of selenocysteyl-tRNA[Ser]Sec [21]. By this mechanism, a selenoprotein 
contributes to the synthesis of other selenoproteins including itself. In comparison to 
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the mRNA of other selenoproteins, mRNA of the human Selenoprotein P (Sel P) 
contains two SECIS insertion sequences (1 and 2) and 10 UGA codons coding for 10 
SeCys [22]. 
 
1.1.4 Selenium containing proteins 
 
So far, there are 25 identified selenoproteins in humans (listed in table I), divided into 
17 selenoprotein families. Among these, the redox active thioredoxin reductases 
(TrxR), glutathione peroxidases (GPx) and iodothyronine deiodinases (DIO) have been 
extensively characterized. However, the functions of many selenoproteins are yet to be 
determined. Selenium containing proteins can be divided into two groups, depending 
on localization of SeCys, where it either is localized in the C-terminal region close to 
the UGA stop codon, or in the N-terminal region, between an α-helix and a β-strand.  
 
Selenium is recognized to have antioxidant properties, since the discovery of the first 
selenoprotein glutathione peroxidase (GPx) [23, 24]. There are five selenium 
containing GPx in humans with different tissue distributions, GPx1 (cytosol and 
mitochondria), GPx2 (gastrointestinal epithelium), GPx3 (plasma), GPx4 (phospholipid 
hydroperoxidase) and GPx6 (olfactory epithelium). GPxs do not only reduce hydrogen 
peroxide or more complex hydroperoxides to water and corresponding alcohols (in 
conjunction with glutathione) (described in section 1.2.2.) but they have additional 
more regulatory mechanisms, like redox based regulation of transcription factors [25] 
and the insulin signaling pathway (GPx1) [26]. For instance, GPx4 regulates NF-kβ by 
activation of interleukin 1 [27] and regulate COX-2 expression and thereby 
inflammation [25]. GPx2 belongs to phase 2 enzymes, regulated by Nrf2 and the ARE 
elements [25]. GPx4 is also essential for sperm maturation [28] and embryonic 
development [29]. During selenium deficiency, GPx2 is considered to be the highest in 
the hierarchy of the GPxs, based on high mRNA stability and speed of biosynthesis 
when selenium is in excess, compared with other GPx isoforms [30]. 
 
The most abundant selenoproteins in plasma are Sel P and GPx3. These proteins are 
used as biomarkers of selenium homeostasis, since both are decreased during selenium 
deficiency. However, in a supplementation study performed in China where the daily 
selenium intake was 10 µg/day, Sel P was shown to require higher selenium 
concentration, before reaching a saturation plateau compared to GPx3 [31], and should 
therefore be a better marker for selenium status. Sel P does not only transport selenium 
within the blood but possesses also glutathione peroxidase activity, heparin binding and 
heavy metal binding. The half-life of Sel P is estimated to 3-4 hours and has a 
preference for testis and brain under selenium deficient conditions [32]. 
Three selenium containing DIOs, DIO1, DIO2 and DIO3, exists in humans. DIO1 and 
DIO2 catalyzes the activation and DIO3 inactivates the thyroid hormones T3 and T4 and 
rT3 by removing specific iodine moieties [33]. 
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1.1.5 Selenium metabolism 
 
Selenium is absorbed from the diet, both in organic and inorganic forms. After 
absorption by the digestive system, selenium is transported to the liver by the blood via 
the portal vein. Organic selenium forms may also be incorporated nonspecifically into 
erythrocytes and into blood proteins [34, 35].  It is however not clear in which form and 
redox state inorganic selenium is transported to the liver. The liver supports the 
selenium homeostasis in the body, as it both takes up selenium from blood and 
synthesize new selenoproteins, especially selenoprotein P [36]. Sel P, the major source 
of selenium in the plasma, is further taken up into other organs, presumably by receptor 
mediated mechanisms, which is tissue dependent [37]. 
 
The three main pathways for selenium compounds to be metabolized  consists of redox 
active compounds, selenoamino acids and precursors of methylselenol [17]. Redox 
active selenium compounds include selenite and selenodiglutathione. Selenate (SeO42-) 
is the highest oxidized inorganic form of selenium, can be reduced into selenite (SeO32-
) intracellularly by glutathione and further reduced to selenide, catalyzed by the 
thioredoxin system [38]. Selenite is very redox reactive and will readily react with 
intracellular thiols and glutathione, to form the intermediate selenodiglutathione (GS-
Se-SG) and selenide (HSe-) [39]. Both selenite and GS-Se-SG are substrates to the 
thioredoxin system and directly reduced to selenide (HSe-) [40, 41]. In addition, GS-Se-
SG may also be reduced by glutathione reductase (GR) to selenide [42]. 
 
The predominant organic forms of selenium include the amino acid SeCys and the 
methylated species SeMet and SeMSC. In order to further be metabolized, both SeCys 
and SeMSC require a β-lyase cleavage to form selenide or methylselenol, respectively 
[43], while SeMet is either cleaved by γ-lyase to methylselenol [44], or to SeCys via 
the trans-selenation pathway under normal nutritional conditions (figure 2). 
Selenide is a highly reactive selenium intermediate, which is spontaneously oxidize in 
the presence of oxygen, leading to superoxide formation and at moderate to high doses 
cause cellular damage. Selenide might form elemental selenium (Se0) [45], or further 
undergo methylation to methylselenol, dimethylselenide and trimethylselenonium [46, 
47], whereas monomethylselenol is believed to be the active metabolite of selenium in 
cancer treatment [48]. This methylation reactions are carried out enzymatically by three 
methyltransferases (MT-1, MT-2, MT-3), and demethylated by demethylases [49].  
 
In case of high selenium levels, selenide is methylated and further transformed into 
selenosugars, mostly as 1-methylseleno-N-acetyl-D-galactosamine and excreted by the 
urine [50]. After excessive intake, the volatile dimethyl-diselenide and dimethyl-
selenide may be formed, which are excreted through the lungs and gives rise to a garlic 
odor of breath. Selenide may also be phosphorylated before incorporation into SeCys, 
for specific selenoprotein synthesis. In addition, an unspecific incorporation of 
selenocysteine/cysteine or selenomethionine/methionine may appear, due to their 
similar structure [51].  
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Figure 2. Illustration of the selenium metabolism, centered round the highly 
reactive intermediate selenide. The figure includes selenium uptake of redox active 
selenium species and thiol homeostasis, glutathione biosynthesis, selenoproteome 
biosynthesis, trans-selenation pathway, and methylation reactions and formation of 
selenosugars to excretion products. 
 
1.2 THIOL REDOX REGULATION 
Cysteines are important in cellular thiol homeostasis due to the ability to sense the 
redox balance. Thiol modification involves one or two cysteine moieties, and is 
dependent on the surrounding environment and pKa value of the thiols. During 
oxidation, a thiol group (-SH) will release electrons, and form a disulfide bond (-S-S-) 
or mixed disulfides, while in thiol/disulfide exchange, the redox status between two 
thiols/disulfide pairs changes [52].  
 
Oxidation:   2 R-SH   R-S-S-R + 2 H+ + 2e-  
 
Thiol/disulfide exchange:  R-SH + R´S-S´R         RS-SR´ +R´-SH 
   RS-SR´+ RSH             RS-SR + R´-SH 
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The consequence of thiol oxidation may lead to conformational changes in proteins, 
altering their folding and functionality. Due to a lower pKa value (~3.5-5.1) compared 
to other cytoplasmic protein thiols (pKa <8.0), redox sensitive cysteines are de-
protonated, forming thiolates (-S-) under physiological pH conditions, and therefore 
highly susceptible to react with reactive oxygen or nitrogen species (ROS and RNS) 
[53, 54]. Cysteine has highly conserved localizations within the active sites of many 
enzymes. Depending on the redox state, cysteines determine the protein folding within 
the cytosol as well as in the lumen of the endoplasmic reticulum (ER). 
 
The biological significance of cysteine is revealed by the great number of thiol-based 
redox regulated processes within the cell [55, 56], as exemplified the NF-kβ pathway 
induced by redox active kinases [57] and the JNK signaling pathway. Both of these are 
also activated by ROS mediated initiation of TNF [58], where NF- kβ induces survival 
mechanisms while JNK activation leads to mitochondrial cytochrome C release and 
apoptosis. Furthermore, thiol based redox processes also regulate the binding activity of 
transcription factors and induction of gene expression (e.g. AP-1, NF- kβ [59] and c-
FOS/c-Jun [60, 61]). The redox state of cysteines also regulates the calcium 
homeostasis [62, 63], binding activity of albumin [64], formation and activity of iron-
sulphur cluster proteins [65], iron metabolism [66] and selenocysteine synthesis [67]. 
 
Environmental stressful conditions due to ROS formation, induce a cellular response by 
activation of the Keap1-Nrf2 –ARE (antioxidant response element) pathway, and 
activates transcription of antioxidant related proteins (phase 2 enzymes) and glutathione 
synthesis [68]. Among these proteins are thioredoxin (Trx), thioredoxin reductase 
(TrxR), glutathione S-transferase (GST), glutathione peroxidase (GPx), and 
peroxiredoxin (Prx). The activation is initiated by a covalent adduct formation of 
cysteine thiols in Keap1, which is bound to Nrf2 under normal conditions. The 
disulphide bond formation initiate the release Nrf2 to the nucleus and activate ARE 
elements which induces the transcription of phase 2 enzymes [69]. In addition, other 
cellular responses that may be activated under stress are the heat shock response (HSR) 
and unfolded protein response (UPR), described more in detail under ER-stress). HSR 
is transcriptionally regulated by activation of HSE (heat shock element) through heat 
shock factor 1 by multistep modifications [70] and transcription of proteins like 
chaperones and proteases. 
 
1.2.1 Reactive oxygen species (ROS) and oxidative stress  
 
ROS are free radicals or reactive molecules, which are formed normally within cells 
during reduction and oxidation processes involving oxygen. The definition of free 
radicals is any species with one or more unpaired electrons. A free radical is highly 
reactive and able to form a new radical and induce a radical chain reaction [71].The 
major free radicals in biological systems are superoxide (O2•-), hydroxyl radical (•OH) 
and nitric oxide (NO•) (figure 3).  
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At physiological concentration, ROS are important signaling molecules, implicated in 
cellular reactions as second messengers [72], stimulating mechanisms by activation of 
growth factors and induction of repair functions, cell cycle progression and 
differentiation [73, 74]. For instance, ROS mediated differentiation has been shown in 
leukemia [75, 76], osteoblasts [77], osteoclasts [78, 79] and the maturation of stem cells 
[80, 81]. In contrary, higher ROS level causes oxidative stress. This can occur when the 
intracellular defense systems are decreased or by exogenous sources, leading to 
oxidation of lipids, DNA and proteins [82]. Exogenous ROS production are derived 
from pollutants [83], tobacco smoke [84], iron salts [85], and UV- and ionizing 
radiation [86].Oxidative stress is implicated in several diseases, like cancer, diabetes, 
atherosclerosis, cardiovascular diseases, Alzheimer and Parkinson (Reviewed in [87]). 
During evolution, cells have developed cellular antioxidants as the defense against 
ROS, which will be described more detailed in the following sections. Also, small 
molecules, vitamin A [88], E [89] and C [90], and flavonoids [91], absorbed from the 
diet, are included in the detoxification of ROS.  
 
Superoxide 
The major intracellular source of ROS is related to leakage of electrons from the 
mitochondrial complexes during oxidative energy metabolism and ATP synthesis [92] 
and is the down side of the evolutionary adaption to an aerobic environment [93]. 
Superoxide is formed in almost all cells when oxygen (O2) accepts one electron to the 
pi anti-bonding orbital [94]. Formation of superoxide may also be mediated by 
NAD(P)H oxidase in neutrophils and phagocytic cells, during oxidative bursts as a 
defense mechanism [95], or, under certain conditions [96, 97] e.g. ischemia reperfusion 
[98] by xanthine oxidase to reverse hypoxanthine, which is an ATP breakdown 
product. The biological defense against superoxide is superoxide dismutase (SOD), 
which transforms superoxide into hydrogen peroxide in aqueous solution [94]. SOD1 is 
located mainly in the cytosol, whereas SOD2 is localized in mitochondria. 
 
Hydrogen peroxide/Hydroxyl radicals 
Hydrogen peroxide is produced in large quantities in the body, like in the liver; 80 
nmol/g/minute and the concentration in the lens of the eye is 20 µM. Hydrogen 
peroxide readily interacts with transition metals, like iron and copper, and will form 
hydroxyl radicals in a chain of reactions, described as the Fenton reaction, discovered 
in 1894 (Reviewed in [98, 99]) or as the iron-driven Haber-Weiss reaction (figure 3). 
Hydroxyl radicals are extremely reactive and reacts readily with all types of biological 
molecules, generating new radicals [100]. Hydrogen peroxide is catalyzed by GPx, 
catalase (CAT), glutathione (GSH), the thioredoxin system and Prx.  
 
Nitric oxide 
Nitric oxide (NO) is an important biological molecule, involved in the regulation of 
blood pressure as endothelium derived relaxation factor (EDRF) [101], thrombosis and 
as neuronal transmitter , important for the activity of neurons [102]. It is also essential 
for the activity of guanylyl cyclase (by binding to ferrous heme), with higher affinity 
than oxygen, in the production of cyclic guanosine monophosphate (cGMP) [103]. NO 
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cannot be stored, and therefore its synthesis is regulated by nitric oxide synthetase 
(NOS). There are several isoforms of NOS, nNOS (neuronal), eNOS (endothelial) and 
iNOS (inducible, induced by pro-inflammatory cytokines or endotoxins), and vary with 
their physiological functions [104]. NO is able to diffuse over cell membranes [102], 
but with negligible reactivity with other molecules. However, under oxidative stress, 
superoxide may reduce NO and produce peroxynitrite (-OONO) a powerful and toxic 
oxidant [105, 106].  
 
 
 
Figure 3. Intracellular sources, reactions and products of ROS. Superoxide may be 
formed by electron leakage from the mitochondria, and is reduced by SOD into 
hydrogen peroxide and water. Hydrogen peroxide is mainly reduced by GPx, GSH, Prx 
and CAT. Under oxidative stress, superoxide may react with hydrogen peroxide, 
catalyzed by free iron (Fe3+) (Haber Weiss reaction), forming highly reactive hydroxyl 
radicals which can damage proteins, lipids and DNA. In addition, hydroxyl radicals 
may also be formed from hydrogen peroxide catalyzed by Fe2+ (Fenton reaction). 
Intracellular sources of nitric oxide may react with superoxide under oxidative stress 
conditions, and be reduced to nitric oxide radical and form peroxynitrite (-OONO) 
which is a very reactive and toxic radical. 
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1.2.2 Glutathione 
 
Glutathione (GSH) is an ubiquitous small tripeptide and the major source of 
intracellular thiols in mammalian cells. It is comprised of the amino acids glutamate, 
cysteine and glycine. GSH is present in ~10 µM concentrations in plasma and 1-10 mM 
within cells [107]. The major function is to serve as a thiol antioxidant redox buffer, 
thereby protecting against oxidative damages and maintaining the redox balance [108-
110]. GSH can also directly scavenge ROS and NOS by formation of GSNO or by 
formation of a thiyl radical (GS•) where two of these latter will form GSSG [111]. 
Oxidized GSH (GSSG) is reduced by glutathione reductase (GR) and NADPH (figure 
4), and by protein-disulfide isomerase (PDI) within the endoplasmic reticulum (ER) 
[112]. By a thiol-disulfide exchange, reduced GSH can further interact with 
glutaredoxin (Grx), GPx, glutathione s-transferase (GST), among others. The ratio of 
reduced GSH and oxidized GSH (GSSG) determines the intracellular thiol redox state, 
and the cellular fate, including proliferation [113, 114], differentiation [115, 116] and 
apoptosis [117-119]. 
 
Glutathione is synthesized within the cell downstream of the trans-sulfuration pathway, 
where glutamate and cysteine are actively ligated by γ-glutamyl cysteine synthetase (γ 
–GCS), and addition of glycine catalyzed by glutathione synthase, with ATP 
hydrolysis. However, the limiting step for GSH synthesis is the availability of cysteine 
[120]. GSH can also be taken up, via controlled import and export over the plasma 
membrane through glutathione transporters. These transporters belong to the multidrug-
resistant proteins (MRP), ATP binding cassette transporters (ABC) and the organic 
anion-transporting polypeptide proteins (OATP) [119, 121]. GSH is catabolically 
processed extracellularly, where glutamate is cleaved of by γ-glutamyltransferase 
(GGT) followed by cleavage of cysteinyl-glycine dipeptidase, bound to the plasma 
membrane [121]. 
 
Under several intracellular processes like regulation of metabolism, cell signaling and 
oxidative stress, a non-enzymatically or enzymatically oxidative post-translation 
modification of proteins occurs, where glutathione is covalently conjugated to the 
sulphur within cysteines, forming s-glutathionylation [122, 123]. This process affects 
the structure and function of proteins. S-glutathionylation functions as a regulatory 
energy-saving mechanism to activate or deactivate proteins in a very efficient manner 
[124]. Some proteins modulated by s-glutathionylation are p53, c-Jun, MEKK1, 
SERCA, GAPDH, complex I, II, IV, hemoglobin, caspase 3, Fas, β-tubulin and actin 
[107, 108, 125]. Under normal non-stress conditions, half of the GSH content in the ER 
is protein-bound [126], while the amount of protein-bound GSH fluctuates within the 
mitochondria, depending on the mitochondrial respiration [127]. 
 
Under oxidative stress conditions, s-glutathionylation occurs either by Grx to protect 
cysteine residues on protein surfaces in order to protect against irreversible oxidation or 
modifications, or spontaneously by oxidized GSSG, targeting cysteines and form RS-
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SG. S-glutathionlyation is reversible by Grx [128], which can both catalyze 
glutathionylation and deglutathionylation reactions [129]. In addition, glutathione s-
transferases (GST) may also s-glutathionylate a wide range of electrophilic metabolites 
(hormones, carbonyls, metals, xenobiotics etc) 
 
1.2.3 The thioredoxin system 
 
Thioredoxin superfamily of proteins comprises several proteins with the similar 
secondary characteristic folding structure, consisting of four β-sheets surrounded by 
three α-helices and several of these comprises the active site residue, Cys-x-x-Cys 
[130]. These cysteines are essential for the activity and functions of these groups of 
thiol-disulfide oxidoreductases in reversible reduction of protein disulfide bonds of 
many substrates. The thioredoxin system comprises of thioredoxin reductase (TrxR), 
thioredoxin (Trx) and NADPH (figure 4). 
 
1.2.3.1 Thioredoxin (Trx) 
Trx is a 12 kDa ubiquitous protein which has been identified in almost all organisms, 
with the catalytic sequence Cys-Gly-Pro-Cys [131, 132]. The general function of Trx is 
as a thiol redox reductant, and among other various functionalities, Trx has antioxidant 
functions like reduction of H2O2 or peroxiredoxin [133]. Trx promotes cellular growth 
both in normal cells and in cancer cells, through several redox regulating mechanisms 
[134]. Two mammalian isoforms of Trx have been identified, namely Trx1 which is 
predominantly cytosolic, but can translocate to the nucleus under stress conditions 
[135] and be secreted by cells under oxidative stress and inflammation [136], whereas 
Trx2 is present within mitochondria [137]. Trx1 regulates DNA synthesis by reduction 
of ribonucleotide reductase (RNR) [138], essential for the synthesis of 
deoxyribonucleotides. Trx also regulates transcription factors like NF-kβ [139], p53 
[140] and activator protein 1 (AP-1) [135] by reduction of cysteine residues either 
directly or indirectly by of redox factor 1 (Ref-1). Trx can also inhibit apoptosis signal-
regulating kinase 1 (ASK-1) [141].  
A number of reports imply an involvement of Trx1 in chemotherapeutic resistance, due 
to increased levels in several tumors [142-144]. Deletion of Trx2 is lethal during 
embryonic development, and connected with the time when mitochondria are matured 
[145]. Trx2 protects the mitochondria against activation of the intrinsic apoptosis 
pathway, by inhibiting cytochrome C release [146] and increase of the mitochondrial 
membrane potential (MMP) [147, 148]. Trx2 is also implicated in ischemia-induced 
angiogenesis [146]. 
 
1.2.3.2 Thioredoxin Reductase (TrxR) 
There are three major TrxR in mammalians, which differently to the bacterial, fungi 
and plants, are seleno-containing proteins and higher in molecular weights. Mammalian 
TrxR is a homodimeric flavoenzyme (56kDa) with a FAD-binding and a NADPH-
binding domain, containing an active site with the sequence Gly–Cys–SeCys–Gly. The 
presence of SeCys is crucial for the redox activity of TrxR, since an exchange to Cys 
results in a very low-active enzyme [149]. There are three isoforms of TrxR, the 
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cytosolic TrxR1, the mitochondria localized TrxR2 [150], and the testis specific 
isoform thioredoxin glutathione reductase (TGR) [151]. 
Mammalian TrxR has a broad substrate specificity, and except from reduction of Trx, 
the enzyme reduce a wide range of low molecular weight substrates, including lipoic 
acids [152], lipid hydroperoxides [153], NK-lysin (a cytotoxic and antibacterial peptide 
of T-lymphocytes) [154], insulin [155], dehydroascorbic acid [156], and ubiquinone 
[157]. TrxR also interact with and reduce several selenium compounds [40, 41]. 
Furthermore, both TrxR1 and TrxR2 are essential during embryonic development in 
mice [158, 159]. TrxR1 has been shown to be overexpressed in several cancers, and is 
suggested to be a prognostic marker [160-162]. In addition to this, studies with 
inhibition of TrxR1 reversed the tumor development [163]. Efforts with TrxR-specific 
inhibitors have been performed in studies with positive outcomes [164-166], especially 
gold-containing compounds, which has high affinity for selenyl sulfides and target the 
highly reactive SeCys in the active site [165, 167, 168]. The inhibition of TrxR further 
sensitizes tumor cells against radiation [169]. Because of the low pKa value of the 
selenol (5.2), it easily becomes ionized at physiological pH to a selenolate. This 
cysteinyl-selenol formation is highly reactive and is easily targeted by electrophilic 
agents. Altogether, this has designated TrxR to be a promising target in cancer 
treatment [17, 134].  
 
 
Figure 4. The thioredoxin and the glutaredoxin system. The thioredoxin system 
(purple square) comprises NADPH, which reduces TrxR by electron transfer, and TrxR 
further reduces oxidized Trx. The glutaredoxin system (blue square) comprises 
NADPH, which reduces GR that further reduces GSSG into 2 GSH (glutathione 
system). Oxidized Grx is reduced by 2 GSH, and subsequently functions as an active 
thiol disulfide reductant. 
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1.2.4 The glutaredoxin system 
 
Glutaredoxins are small ubiquitous thiol-disulfide oxidoreductases and belongs to the 
thioredoxin superfamily of proteins [170]. The glutaredoxin system (figure 4) operates 
with glutathione (GSH) and glutathione reductase (GR) and NADPH (see section 1.2.2) 
for continuous reduction of glutaredoxin (Grx) in order to catalyze reductions of 
disulfide bonds and mixed disulfides. Grx regulates a number of intracellular processes 
induced by oxidative stress, like differentiation, transcription and apoptosis. There are 
four glutaredoxins in humans, localized in different cellular compartments [171]. 
Human Grx can function either by a di-thiol or a mono-thiol mechanism depending on 
their active sites (table II and figure 5). Grx has a GSH binding moeity, dependent on 
interaction with the active site (N-terminal Cys22), important for the mono-thiol 
reduction by GSH [172]. Grx can s-glutathionylate and de-glutathionylate proteins 
under oxidative conditions, presumably predominantly performed by Grx1 and Grx2 
[173].  
  
Table II.  
Active site motifs of the human glutaredoxins. 
 LOCATION ACTIVE SITE MECHANISM 
Grx1 Cytosol Cys-Pro-Tyr-Cys di-thiol, mono-thiol 
Grx2a 
Grx2b,Grx2c 
Mitochondria 
(cytosol, nucleus) 
Cys-Ser-Tyr-Cys di-thiol, mono-thiol 
Grx3 (PICOT) Cytosol Cys-Gly-Phe-Ser mono-thiol 
Grx5 Mitochondria Cys-Gly-Phe-Ser mono-thiol 
 
 
Grx1 (12 kDa) is a dithiol oxidoreductase, and the most well studied among all 
glutaredoxins. Grx1 is mainly cytosolic, but can be translocated to the nucleus, and 
regulate transcription factors e.g. AP-1 and NFkβ [174]. Grx 1 may also regulate NFkβ 
transcriptional activity by a deglutathionylating process of IKK, under oxidative stress 
[175]. Grx1 has been detected in plasma and is therefore believed to be exported over 
cell membranes [176]. Like Trx1, Grx1 regulates DNA synthesis by reduction of RNR 
and the transcription of JNK and p38 MAP kinase pathway upon binding to ASK-1. 
Although, differently compared to Trx1, Grx1 dissociates from ASK-1 under metabolic 
oxidative stress, dependent on the glutathione redox state [177]. Overexpression of 
Grx1 increases the resistance to Adriamycin in MCF-7 cells [178], and overexpression 
of both Grx1 and Grx2 is inversely correlated to proliferation in lung cancers [179]. 
Grx2 is a 14 kDa iron-sulphur cluster protein (Fe/S) which in its inactive form is 
comprised of  two Grx2 molecules  and [2Fe-2S], functioning as a redox sensor during 
oxidative stress [180]. Differently to Grx1, Grx2 contains a serine instead of proline 
within the active site, important for (Fe/S) binding [181] and for the reduction by 
TrxR2. Grx2 is present in three splice forms, where Grx2a is localized to the 
mitochondria, whereas the splice forms Grx2b and Grx2c lacking the mitochondrial 
translocation signal, is either cytosolic or nuclear located. Grx2b do not have the (Fe/S) 
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regulatory binding ability [182].The monothiol Grx3, also recognized as PICOT, is a 
cytosolic 38 kDa protein, and is also characterized as an (Fe-S) protein [183]. Recently, 
Grx3 was shown to be crucial for the cell cycle progression at the G2/M phase in 
embryonic development [184]. The second monothiol Grx in humans is the 17 kDa 
sized Grx5. Like Grx2 it is translocated to the mitochondria, and crucial for the 
mitochondrial iron-sulfur cluster biosynthesis [66]. 
 
 
 
 
Figure 5: Illustration of di-thiol and mono-thiol reduction mechanisms by 
glutaredoxins. Grx can reduce disulfides using one or two cysteines in the active site. 
In the di-thiol reaction, the N-terminal Cys, targets the disulfide of the substrate and 
forms a mixed disulfide, with a following attack by the C-terminal Cys in the active site 
of Grx. This leads to an oxidation of Grx, and a reduction of the substrate, which is 
released from Grx. In the mono-thiol reduction, the N-terminal Cys targets P-SG and 
forms Grx-SG with a mixed disulfide bond, which is further reduced by a second GSH. 
 
 16 
 
There seems to be a cross-talk between the thioredoxin and the glutaredoxin systems 
since they compensate for one system in the absence of the other, even though they 
have their specific functions [170]. In addition, it has been shown that Grx2a can be 
reduced by TrxR2 [185] and also the occurrence of glutathionylation of thioredoxin 
has been demonstrated in vitro [186]. 
 
1.3 CANCER 
 
Except from stem cells, normal or healthy cells do not divide frequently and are mostly 
present in a G0/G1 stage. There are several cellular mechanisms developed to block and 
prevent uncontrolled cell growth. To evade these, tumor cells have to develop 
capabilities, described as hallmarks, which comprise resistance to cell death by evading 
growth suppressors, sustained proliferative signaling, enabling replicative immortality, 
induce angiogenesis and to invade other tissues and metastasis [187]. Lately, additional 
properties have been added to these hallmarks; capability to change the metabolism to 
increase the nutrition supply, escape immunological destruction, tolerate tumor-
promoting inflammation and genome instability and mutations [188].  
 
Cancer can be derived from different cell types and further classified accordingly to 
which tissue they have developed from. Carcinoma is tumors derived in epithelial cells 
(skin, intestinal, glands), originated from the endodermal or ectodermal germ layers. 
Sarcomas origin from the mesenchymal germ layer, through which bone, muscle, fat, 
vascular and hematopoetic cells are derived from.  
 
1.3.1 Development of carcinogenesis 
Cancer and tumor growth are induced by several reasons, like carcinogen exposure, 
radiation, genetic mutations and viruses, possessing uncontrolled growth and invasion 
of other tissues. Development of carcinogenesis consists of a multi-step process, 
including changes in both genotype and phenotype.  
 
The initiation step in tumor development is caused by changes of the DNA induced by 
endogenous replication errors, instability of bases by free radical attacks, or exogenous 
sources like radiation and chemical carcinogens. The consequences of genetical 
mutations of the DNA could lead to either activation or inactivation of genes or the 
corresponding protein expression, where activating genes are considered as oncogenes, 
while inactivating genes are tumor-supressors. The promotion step is when mutated 
cells start to divide and expand clonally. During the promotion step, additional genetic 
mutations may occur, leading to a preneoplastic stage, and form a benign or malignant 
tumor growth. In the progression state, tumor cells proceeds into an uncontrolled 
growth, with the ability to metastasize. It is also in this step where the primary tumor is 
capable of increasing nutrient supply by angiogenesis [189, 190]. 
 
Stem cell like and chemo- or radio-resistant cancer cells, has been proposed to contain 
low ROS levels, related to increased expression of genes controlling GSH biosynthesis 
[191]. On the contrary, cancer cells under progression have a high basal level of ROS 
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used as signaling to speed the proliferation [192]. Several mechanisms regulating tumor 
growth and metastasis are ROS regulated, to most extent via NADPH oxidase 
promoting angiogenesis [193]. High ROS production and high oxidative stress in 
cancer cells can be an Achilles heel, making them more sensitive to ROS inducing 
chemotherapeutic agents or reduction of their antioxidant defense systems, like TrxR 
[194, 195]. 
 
Acute myeloid leukemia 
Differentiation of myeloid blood cells from multi-potent hematopoetic stem cells is 
regulated by several transcription factors e.g. PU.1 and CCAAT enhancer binding 
protein α (CEBPA), generating monocytes or granulocytes. Acute myeloid leukemia is 
characterized by an uncontrolled outgrowth of hematopoetic stem cells or progenitors, 
and is a collective name for several subtypes of AML, divided after the causative of the 
disease [196]. One of these, acute promyelocytic leukemia (APL) is characterized by a 
chromosomal translocation of t(15;17)(q22;q21). This leads to fusion of the retinoic 
acid receptor alpha (RARα) with the PML gene [197]. This fusion protein will block 
differentiation in a promyelocytic stage. Usually patients with APL are treated with all-
trans retinoic acid (ATRA), a derivative of vitamin A as a primary treatment [198]. 
ATRA targets the PML-RARα transcripts and releases the dominant transcription 
repressor, leading to specific differentiation of promyelocytes. Nevertheless, ATRA 
treatment often leads to relapse in many patients, and is in many cases due to up-
regulation of multidrug resistance protein 1 (MDR1) and increased activity of 
cytochrome P-450, along with diminished effect of ATRA [197]. By combining 
chemotherapeutic agents with ATRA treatment has led to complete remission. 
However, side effects, like in all cancer treatment can be severe. 
 
1.3.2 Conventional treatment 
Generally, cytostatic drugs are targeting cellular pathways implicated in cell division 
and metabolism, since tumor cells proliferate to a much higher extent than normal cells. 
Downside to this, non-tumor cells with high cell renewal are affected under cancer 
treatment, like hair-, gastro epithelial- and blood cells, related to the most common 
side-effects during treatment.  
 
One of the first reports using cytostatic agents was published in 1948, where a folic 
acid antagonist had been used in treatment of acute leukemia in children, resulting in a 
temporary remission [199]. Another similar report came out in 1946, called “nitrogen 
mustard therapy” in the use of treating several blood cancer diseases, long before its 
mechanisms were known [200]. There are several groups of cytostatic drugs, and 
depending on the molecular structure they have different abilities to target a variety of 
cellular compartments and structures in tumor cells. The major groups of cytostatic 
drugs and their main targets are summarized in figure 6 [201]. 
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Figure 6. Mechanisms of action and cell cycle targets of some common cytostatic 
drugs. The most common cytostatic drugs comprise alkylating agents, hormones, 
antimetabolites, mitotic inhibitors and topoisomerase inhibitors, targeting differently in 
the cell cycle phases. These are marked with arrows in the figure. 
 
A synergistic effect and a more efficient response to the chemotherapy can be enhanced 
by using photosensitizers, which will generate ROS upon radiation [202]. Several of the 
aforementioned cytostatic drugs belong to the photosensitizers, e.g. mitomycin C, 
cisplatin, doxorubicin, etoposide, methotrexate. 
  
1.3.3 Drug resistance 
 
1.3.3.1 Multidrug resistance proteins 
One major problem in cancer treatment is the development of drug resistance against 
cytostatic agents. This is associated with either impaired induction of apoptosis or 
overexpression of membrane bound multidrug resistance (MDR) proteins. These are 
ATP-binding cassette (ABC) transporter proteins which are ATP-driven efflux pumps 
for many substrates, e.g. phospholipids, peptides, steroids, polysaccharides, amino 
acids, nucleotides and xenobiotics among others. MDR proteins in cancer cells can 
either be initially expressed or induced during chemotherapy treatment. There are 48 
human ABC genes identified, belonging to the ABC superfamily, divided into 7 ABC 
subgroups of proteins (ABCA-ABCG). These are classified according to the structural 
differences and sequence homology [203]. 
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The most well studied ABC-transporters related to drug resistance are the p-
glycoprotein (P-gp) resistance protein 1 (MDR1) (ABCB1), multi resistant protein 1 
(MRP1) (ABCC1) and breast cancer resistance protein (BCRP) (ABCG2), also known 
as ABC-P (ABC transporter in placenta) [204]. MDR1 was early found to be highly 
overexpressed in colon, kidney and hepatocellular cancers [205], in some untreated 
cancers (neuroblastoma, acute lymphocytic leukemia (ALL), acute nonlymphocytic 
leukemia (ANLL), and non-Hodgkin's lymphoma and to some extent in relapses after 
treatments (leukemia, breast cancer, neuroblastoma, and undifferentiated lymphoma) 
[206]. MRP1 has broad substrate specificity, e.g. hydrophobic compounds, some 
dependent on the presence of reduced glutathione (GSH), and glucuronide-, 
glutathione- and sulfate conjugates [207]. 
 
1.3.3.2 xCT 
Another important membrane transport protein is the cysteine/glutamate antiporter, 
xCT, controlling the cysteine/cystine homeostasis and thereby the regulation of GSH 
biosynthesis (See figure 1). xCT is found to be overexpressed in several tumors, 
leading to a regulation of both proliferation and resistance against chemotherapeutic 
agents [208]. Inhibition of cystine uptake has been shown to decrease the chemotherapy 
resistance, either by inhibiting the uptake of cystine with glutamate or by 
downregulation of one subunit of xCT (SLC7A11) with siRNA. A similar increased 
susceptibility to chemotherapeutic agents was enhanced by inhibition of γ-
glutamylcysteine synthetase and glutathione synthesis using buthionine sulfoximine 
(BSO) [209].  
 
Targeting these aforementioned membrane transport proteins with possible inhibitors is 
of high therapeutic interests with the aim to overcome resistance against cytostatic 
drugs. Due to the multi-substrate transportability of ABC transporters, several clinically 
relevant inhibitors have been suggested. A large number of clinical trials have been 
performed with identified inhibitors, combined with cytostatic treatments, although the 
outcome has not been too convincing [210]. This further underlines the efficacy of 
tumor cells to overcome treatments. 
 
1.3.4 Selenium in cancer prevention 
 
Selenium was debated for long to be a carcinogen until the early 1970´s (reviewed in 
[211]). The effect of selenium toxicity was described already in 1295 when Marco Polo 
travelled by horse along the Silk Road in western China. He and his men noticed the 
toxic consequence on their horses when they lost the hooves and hair after eating 
poisonous grass (selenium accumulating plants), although this description of selenosis 
have been condemned, due to lack of scientific evidences [212].  
 
The interest of selenium with its dual role in both cancer prevention and cancer 
treatment has been extensive, and is still continuously explored. Supplementation with 
selenium in low doses has been shown not only to prevent cancer, but also to be 
beneficial against the development of other diseases, like stroke [213], inflammation 
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reduction [214], and heart diseases [215]. In addition to this, selenium can also inhibit 
cell growth and induce cell death in cancer cell cultures, used in higher doses. Selenium 
can act as both an antioxidant and a prooxidant. At higher doses, selenium becomes a 
prooxidant, since there is a narrow window between requirement and toxicity. A daily 
selenium intake of 100-200 µg/day for humans is considered to inhibit damage of DNA 
and cancer, and 400 µg as to be the upper safety daily dose [216]. However, several 
additional factors determine the toxicity, e.g. how selenium is administered, selenium 
compound of choice, basal selenium level, and selenium uptake into organs/tissues. 
 
1.3.4.1 Animal studies 
Several animal studies have found selenium to prevent against tumor development, 
induced by food administered carcinogens. Clayton and Bauman reported in 1949 that 
rats fed with an Azo-dye, followed by 5 ppm sodium selenite per day for 4 weeks, 
reduced the incidence of liver tumors with 50%. [217]. Shamberger and Rudolph, 
showed in 1966, a reduction in the incidence of papillomas induced by 7,12-
dimethylbenznathracene and croton oil, in mice fed with 1 ppm selenium in the diet 
[218]. Strangely though, one early animal study performed with rats, showed that 
selenium induced liver damages, which could be prevented by methionine or vitamin E 
[219]. Contrary to this, selenite has been shown to prevent tumor development in rats 
during the promotion phase [220]. In a more recent study showed that selenite 
treatment of rats, reduced the tumor growth up to 12 months after initiation, and did not 
affect the liver regeneration after partial hepatotectomy, This study suggest that selenite 
to be suitable for cancer prevention in patients suffering from chronic liver diseases 
[221], supported by a long term study, showing that selenite did not accumulate in the 
liver [222]. 
 
1.3.4.2 Human studies 
A selenium prevention study was performed by Clark et al, [223], with the primary aim 
to elucidate a possible protection against basal cell carcinoma and squamous cell 
carcinoma of the skin. 1312 patients from the south-east of U.S. (known to have 
relatively low content of selenium in the soil), that previously had suffered from skin 
cancers, were followed for 4.5 years during treatment or placebo with 200 µg of 
selenium (selenized yeast) per day, and a follow up after 2 years. They found no 
reduction in incidence of skin cancer, but a reduction by 63% in prostate cancer, 58% 
in colorectal cancer and 46% in lung cancer were seen in the selenium group compared 
to placebo treated. The patients treated with selenium also exhibited a 37% reduced 
cancer incidence and 50% reduced cancer mortality. A well debated recent study is the 
SELECT trial (The Selenium and Vitamin E Cancer Prevention Trial), which ended in 
2008, with the objective to evaluate long-term effects on risk of prostate cancer, by 
treatment with selenomethionine and vitamin E [224]. The disappointing outcome of 
this study where no reduction of the incidence in prostate cancer of either selenium or 
vitamin E, but a non-significant increase in prostate cancer by vitamin E and an non-
significant increased risk of diabetes type 2, with combined treatment. The design of 
the study, concerning selection of selenomethionine, base-line of selenium levels in 
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blood and the absence of information concerning BMI has been criticized by many 
[225-227].  
 
From these studies and others, it has been recognized that those patients who responded 
the best, had the lowest basal selenium levels in plasma, while patient with higher basal 
levels instead showed toxic symptoms and were more prone to develop diabetes type 2. 
It has also been considered if some people might require higher selenium intake to 
efficiently synthesis selenoproteins, due to health conditions and diseases [228, 229]. 
 
1.3.4.3 Mechanism of selenium in prevention 
Mechanism of selenium in prevention has been connected to the protective role of 
selenoproteins with antioxidant activity, GPx and TrxR [230, 231], and related to their 
maintenance of a reduced cellular environment in protection against oxidative stress. 
GPx and TrxR also prevent DNA damages, by regulation of repair enzymes. However, 
the regulation in cancers seems to differ, and dependent on p53 expression. Gladyshev 
et al.[232] showed that TrxR was increased while GPx1 was decreased in liver tumor 
malignancies from transgenic mice and human prostate cancer cell, while in a human 
colon cancer, expression of p53 increased GPx1 and decreased TrxR expression.  
 
The importance of selenoproteins in tumor prevention is further supported by studies 
performed in selenoprotein deficient mice. These mice developed cellular changes 
related to prostate cancer [233] and colon cancer, which was prevented by 
supplementation with selenite [230]. 
 
1.3.5 Selenium in diagnostics and cancer treatment 
 
Selenium is not only related to cancer prevention, but also inhibition of cell growth, 
with preferential selectivity to tumor cells. During the 1960´s, the radioactive Se75 
(selenomethionine) isotope was used with the aim at radiological scanning techniques 
of neoplastic and inflammatory diseases, since it was discovered to be readily taken up 
by highly metabolic cells, e.g. pancreas and parathyroid [234, 235]. In 1966, Cavalieri 
et al, discovered Se75- (selenite) to be a tumor-localizing agent, accumulating in tumors 
[236], which was further confirmed by others the following years. Contradictory to this, 
in 1974 a report was published with the statement that Se75 also accumulated in 
nonmalignant (necrotic) lesion and cerebral infarcts of the brain [237]. 
 
Except from the above mentioned study by Cavalieri et al, the ability of selenium to 
selectively target tumor cells has been shown in mesothelioma cells and benign 
mesothelial cells [238] as well as in patient-matched pairs of normal and cancer 
primary prostatic epithelial cells, where treatment with selenite, but not 
selenomethionine, induced apoptosis in the malignant cells [239]. Also, a sensitizing 
effect of selenium on drug resistant cells, have been described in several studies [240-
243]. 
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1.3.5.1 Examples of early animal studies 
Several pharmacodynamic animal model studies have shown promising effects of using 
selenium in cancer treatment, like inhibition of lymphocytic leukemia treated with 
selenite and even more prolonged life span when combined with methotrexate [244]. 
Another study in mice inoculated with fibrosarcoma, where selenite in combination 
with cis-diaminedichloroplatinum (II) (cis-DDP) did not have any increased effect on 
tumor growth, but prolonged the life and decreased the toxicity of cis-DDP [245]. 
Treatment with selenite, has been shown to reduce the tumor promotion in rats by 
decreased density of tumor nodules, in a dose dependent manner [220]. Caffrey et al. 
showed that treatment with selenium, combined with cisplatin of human ovarian cancer 
cells inoculated in mice, prevented cisplatin resistance, while resistance was developed 
when only treated with cisplatin [246]. This supports the usefulness of selenium in 
prevention against drug resistance. It has further been shown that 
selenomethylselenocystiene (SeMSC) significantly inhibit tumor growth and 
microvessel density and normalized vasculature in a colorectal xenograft mice model 
[247]. 
 
1.3.5.2 Human studies 
In 1956, Weisberger and Suhrland reported a small case series where four leukemic 
patients had received selenocystine per orally with 50-200 mg per day for 10 to 57 
days. All patients responded with “a striking drop” in the total leukocytes, and 
decreased size of the spleen. However, the side effects were severe. But one patient 
with acute leukemia that had developed resistance to previous treatment with 6-
mercaptopurine, regained the sensitivity after the selenocystine treatment [248]. In a 
more resent study, an ex vivo model using primary AML cells from 39 patients, selenite 
treatment were shown to induce the lowest mean survival compared to conventional 
treatments of AML [249]. The study further verified a significant correlation of 
resistance of the cells to all tested drugs, except from selenite, indicating selenite as a 
promising drug in targeting multi drug resistant AML. Although selenite affected the 
expression of several redox proteins, further studies of inducing mechanisms needs to 
be confirmed. 
 
1.3.5.3 Thiols and selenium 
In pure in vitro experiment, Ganther et al. showed that selenium readily react with thiol 
containing compounds to form selenotrisulfide [250] which was further reduced to 
selenopersulfide by glutathione reductase (GR) [42]. In 1997, Seko et al, suggested that 
selenite, reduced by GSH to selenide, produced superoxide as the toxic mechanism of 
selenium [251]. The dependency of thiols in selenium uptake and toxicity was further 
shown in a study from 1983, performed both in cell free system and cellular system, 
and to inhibit protein synthesis [252]. This was also shown in human leukemia cells, 
describing the interaction of reduced GSH with selenite and selenocystine with 
increased toxicity. The toxicity and selenium uptake led to decreased cellular GSH, and 
increased oxygen consumption [253]. Using canine mammary cells as a model, Kuchan 
et al. showed that addition of 100 µM of GSH at the same time as selenite, drastically 
increased uptake of selenium an increased cell death, compared to treatment with 
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selenite alone. However, instead, pre-treatment with GSH for 48 hours protected 
against selenite toxicity [254]. In a recent published paper, the importance of a reducing 
extracellular microenvironment provide the mechanistic explanation that regulates the 
cancer-specific toxicity of selenium, since resistant tumor cells efflux thiols in the form 
of cysteines to a much higher extent [255].  
 
1.3.5.4 Intracellular targets of selenium in cancer treatment  
The intracellular targeting mechanisms of selenium in higher treatment concentrations 
have been studied extensively in tumor cells. Many of these have described the 
intracellular action of reactive selenium species to produce superoxide in the presence 
of thiols, as the cause of cell death [256-258]. However, this is not general for all 
selenium compounds [258, 259]. The excessive production of superoxide will target the 
mitochondria, leading to opening of the mitochondrial permeability transition pore 
[260, 261]. Several selenium compounds have been determined to induce DNA strand 
breaks [262]. However, Lu et al. demonstrated in 1995, that selenite and sodium 
selenide, which are rapidly metabolized to hydrogen selenide, induced DNA single-
strand break and growth inhibition in a mouse mammary carcinoma cell line [263]. 
They further showed that methylselenocyanate and Se-methylselenocysteine which 
predominantly are metabolized to methylselenol, induced growth inhibition without 
DNA damages. The authors suggested these differences to be due to induction of 
different pathways dependent on whether selenium is metabolized to selenide or 
methylselenol to the greatest extent. Wang et al. described induction of apoptosis in 
vascular endothelial cells, by methylseleninic acid (MSA), triggered by G1-arrest, 
DNA fragmentation and caspase-mediated cleavage of poly(ADP-ribose)polymerase 
(PARP) [264]. The G1 arrest was associated with a dose dependent decrease of AKT, 
ERK, JNK and apoptosis related to increased phosphorylation of p38 MAPK, and 
dephosphorylation of above mentioned kinases.  
 
Apart from the previous mentioned studies, other intracellular targets induced by 
various selenium compounds, leading to cell death of tumor cells have been 
determined. Among these targets are the mitochondria and BCL-2 proteins [265, 266], 
caspase activation [266, 267] non-caspase activation [268-270] and p53 [269-272]. 
 
It has been reported that selenium exhibit differentiating effects in a human colonic 
carcinoma cell line, where selenite in high doses induced alkaline phosphatase activity, 
a standard method for determination of differentiation [273]. Above the increasing 
knowledge that ROS signaling regulates differentiation of several cell types and 
maturation processes [76, 274, 275], it has also been shown that some selenoproteins 
are important during embryonic development (e.g. TrxR1 [158], TrxR2 [159], GPx4 
[276], Sep N [277], Sep W [278]), and might therefore also be involved in 
differentiation. 
 
Taken together, the toxicity and mechanisms of selenium compounds is not possible to 
generalize, since the structure of selenium compounds, tumor cell type and genetically 
expression will influence the outcome of signaling, leading to inhibition or cell death in 
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tumor cells. It is therefore of outermost importance to clarify all conditions and factors, 
and how each selenium metabolite will influence signaling pathways, within tumor 
cells. 
 
1.4 PROGRAMMED CELL DEATH 
 
To really distinguish a specific cell death mode can be difficult, especially in tumor 
cells, since genetically changes may alter the normal expression of some proteins 
involved in specific pathway.  In addition to this, several cell death pathways might be 
activated simultaneously or a causative can trigger different cell death modes, 
depending of cell type and other environmental conditions [279]. 
 
Programmed cell death (PCD) is a regulated process, initially related as apoptosis (type 
I). Later on, autophagy (type II), paraptosis (type III) among others have been added to 
the list of PCD. PCD has been described as a diverse event from necrosis, which 
eventually leads to cellular burst and a more uncontrolled type of cell death. However, 
recent studies have lately reported of a regulated necrotic cell death, necroptosis 
(described below in the text). 
The nomenclature of different modes of PCD has been extended during the last years 
with increased number of regulated cell death modes. This continuous extension of the 
PCD nomenclature displays the great variety of pathways/ intracellular reactions that 
may take place, depending on cell type, cellular homeostasis, and effect of 
inducers/compounds. Below in the following text, some of these PCDs related to the 
papers within this thesis are described briefly.  
 
1.4.1.1 Apoptosis 
The morphological feature of apoptosis is defined by shrinking of cells, pyknosis, a 
condensation of chromatin, nuclear fragmentation and formation of apoptotic bodies 
and blebbing. Induction of apoptosis is further divided into an intrinsic and extrinsic 
pathway, where the intrinsic involves loss of mitochondrial membrane potential (MMP) 
regulated by BCL-2 family proteins, leading to release of cytochrome C, formation of 
apoptosome complex (by APAF1 and cytochrome C) and eventually activation of 
caspase 9 and caspase 3. However, the intrinsic pathway could also switch into a 
caspase-independent apoptosis, where instead regulators like apoptosis-inducing factor 
(AIF) will translocate to the nucleus for induction of apoptosis. The extrinsic pathway 
is activated by death receptors in the TNF-receptor superfamily, present in the plasma 
membrane, which activates apoptosis via caspase 8 and caspase 10, with a following 
proteolytic degradation of the cell, either by activation of other caspases or pro-
apoptotic BCL-2 proteins like BID and BIM. In addition to this, apoptosis can also be 
mediated by p53-dependent and p53-independent pathways, where p53-dependent 
pathway initiated by transcriptional activation of plasma membrane proteins or 
mitochondrial proteins (NOXA or PUMA). Cytosolic p53 can also physically interact 
with BCL-2 and BAX proteins. In the p53 –independent pathway, apoptosis is induced 
by DNA damages and activation of caspase 2. However, both of these events will lead 
to activation of the mitochondrial (intrinsic) pathway (Reviewed in [280]). 
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1.4.1.2 Autophagy 
The morphology of autophagy (“self-eating”) cell death is characterized by formation 
and accumulation of autophagosomes, no chromatin condensation and an accumulation 
of double membrane autophagic vacuoles. Further on, autophagy could also appear as a 
survival mechanism during starvation or ROS induction. The autophagy process is 
initiated by formation of three protein complexes, ULK (included by FIP200, ULK and 
ATG13), the PI3K (included by pAMBRA, Beclin-1, VPS15, VPS34) and ATG5-
ATG12/ATG16 complex. Formations of these complexes will initiate the formation of 
autophagosomes comprised by cytoplasmic organelles/materials, followed by a fusion 
with lysosomes for degradation of its content. This degradation is determined by a 
cleavage of Atg8/LC3 and degradation of p62/SQSTM1. There is however a cross-talk 
between apoptosis and autophagy, via BCL-2 family proteins that are bound to Beclin-
1 under normal conditions, which is cleaved by apoptotic caspases [281, 282].  
 
1.4.1.3 Paraptosis 
Paraptosis (para = next to or related to apoptosis) is an alternative PCD (type III) 
different from PCD I and PCD II by the appearance of large vacuoles of ER and 
mitochondria origin, and absence of nuclear fragmentation and caspase activation 
[283]. Paraptosis has been shown to be mediated by MAP kinases, via insulin growth 
factor 1 receptor [284] , and triggered by TAJ/TROY [285]. Reports have described the 
presence of paraptosis activated simultaneously along with other cell death modes.  
 
1.4.1.4 Necroptosis 
Necroptosis is characterized by a necrotic like cell death, with loss of plasma 
membrane and mitochondrial membrane potential (MMP), along with presence of 
autophagic activity [286]. Necroptosis can be triggered by alkylating DNA damage, 
excitotoxins and activation of death receptors. Activation of necroptosis is similar to the 
extrinsic pathway, but without activation of caspase 8 [279]. Necrostatin-1 (Nec-1) a 
specific inhibitor or RIP1 kinase, has shown to be unable in inhibiting ROS induced 
necroptosis, but protects against glutamate-induced glutathione depletion, induced by 
glutamate or BSO, and caspase-independent cell death [287].  
 
Other cell death modes have been named as Mitotic catastrophe, Cornification, 
Anoikis, Netosis, Parthanatos, Pyroptosis. Although, stated with their main biochemical 
features, and dependency of caspases, there are many uncertainness, and still gaps to 
fill of unknown events, in order to distinguish cell death modes [279]. 
 
1.4.1.5 ER-stress 
ER-Stress is not considered as a programmed cell death mode, even though the cellular 
response to the condition is regulated, but an event that eventually can lead to 
programmed cell death. The ER lumen comprises a higher ratio of oxidized GSSG to 
reduced GSH (1:1-3:1) due to the allowance of formation of disulfide bonds during 
protein synthesis and folding in the ER, although the conditions is highly regulated.  
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Many oxidoreductases and chaperones are present in the ER to assist and regulate these 
processes during folding and also to eliminate misfolded proteins, e.g. PDI (protein 
disulfide isomerase), chaperone Bip/GRP78 and ERdjs to mention some of these [288]. 
Misfolding of protein induces ER stress and ER stress response, also recognized as 
UPR (unfolded protein response) which accumulation within the ER. The most used 
markers for detection of ER stress is Bip, which is increased upon ER stress and 
released by the ER transmembranes IRE1 PERK or ATG6. ATG6 upregulates the 
expression of transcription factor CHOP/GADD153 which in turn inhibits BCL-2 
leading to activation of the intrinsic apoptosis pathway. Also Ca2+ release from the ER 
activates caspase 12 and further cleavage of caspase 9 and 3. The extrinsic pathway is 
initiated trough IRE1, by complex formation with TRAF2 and activation of ASK1 and 
c-Jun (reviewed in [289]).  
 
1.4.1.6 Senescence  
As in the case of ER stress, senescence does not belong to PCD, but is a state in which 
cells can enter due to either shortening of the telomeres, or DNA damage, stress 
conditions (e.g. ROS, starvation) or oncogene-expression. The morphological changes 
adapted by senescent cells are distinct from normal dividing cells, gaining increased 
size, flat and multinucleated in addition to almost transparent. The most extensively 
used marker for determination of senescence is measurement of senescence associated 
β-galactosidase activity (SA-β-GAL) from lysosomes (reviewed in [290]). However, 
identification of more markers is needed. It is not known if senescence is an end stage 
of cells, but some studies have reported of reversible senescence related to oncogenic 
signaling. Also, autophagy has been connected to induction of senescence.  
 
1.4.2 Selenium and programmed cell death 
 
Several selenium compounds have been determined to induce programmed cell death, 
studied in various tumor cell lines. Selenite has been shown to induce apoptosis via 
p53-mediated apoptosis in prostate cancer cells [291] and a caspase-independent cell 
death in cervical cancer cells [270]. In addition, selenite has also been reported to 
induce ROS-mediated ER-stress leading to apoptosis [292], and inhibit autophagy 
through PI3K/Akt signaling, with increased apoptosis in promyelocytic leukemia NB4 
cells [293]. Another study describe selenite to cause a superoxide induced mitophagic 
cell death in malignant glioma cells [294]. Furthermore, treatment with selenocystine 
(SeCys) induced apoptosis by ROS formation and DNA strand break in MCF7 and 
Hep2 cells, but not in normal human fibroblast HS68 cells. This ROS formation and 
DNA strand break, was inhibited by GSH and N-acetylcysteine (NAC), but only in 
MCF7 [295]. Selenomethionine has been described to cause ROS-dependent apoptosis 
in A549 cells via the Akt/mTOR/ROS pathway [296]. Methylseleninic acid (MSA), 
which is a precursor of methylselenol, has been shown to induce cell death by ER stress 
in a p53-null prostate cancer cell line [297] and apoptosis via β-Catenin/TCF pathway 
in esophageal squamous cell carcinoma cells [298]. Another study, using a human 
colon cancer cell line, showed methylselenol to induce apoptosis by inhibition of 
MAPK activation and suppression of ERK1/2 [299]. In a comparative study with four 
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carcinoma cell lines treated with selenite, selenomethylselenocysteine and 
selenomethionine, concluded that selenium induced apoptosis by different mechanisms. 
The authors concluded that the selenium compounds predominantly induced caspase-
dependent apoptosis, activated both intrinsic pathway and ER stress, and that p53 
activation was only induced by selenomethionine [300]. 
 
Taken together, these above studies verifies the complexity of selenium compounds 
and the requirement of further in depth studies to elucidate the targeting mechanisms 
that different selenium compounds induce in tumor cells.  
 
 
 
 
 
 
 
 
 
 
When searching on PubMed today by the MeSH terms “selenium”, “programmed cell 
death” and “cancer” resulted in 364 hits, and “selenium” and “cancer” 3943 hits, one 
realize the interest and the potential of selenium in cancer treatment. The mechanisms 
are still to be clarified, but hopefully by continuous research and determined mines and 
resources, we will get there, hopefully within the nearest future. 
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2 PRESENT INVESTIGATION 
 
2.1 AIMS OF THE THESIS 
 
In the light of growing evidences showing that redox active selenium compounds are 
promising anti-cancer drugs, with chemotherapeutic potential, the aim of this thesis was 
to study the cytotoxic mechanism induced by some redox active selenium species in 
tumor cells, and their interaction with the thioredoxin and the glutaredoxin system.   
 
The specific aims of each paper were as follows: 
 
I. To study a possible interactions between selenium compounds and the 
glutaredoxin system, and the role in terms of cytotoxicity in tumor cells. 
 
II. To investigate if methylselenol could be spontaneously formed from 
selenide in the presence of s-adenosylmethionine (SAM), and its reactivity 
with the thioredoxin and the glutaredoxin system and cytotoxicity. 
 
III. To compare the cell death pathways induced by three different redox active 
selenium compounds, under the same conditions. 
 
IV. To study the possible potentiating effect of selenite on all-trans retinoic-acid 
(ATRA) induced differentiation in AML.  
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2.2 COMMENTS ON THE METHODOLOGIES  
 
This section contains a brief description of different methods to determine cytotoxic 
effect and viability after treatment with selenium compounds, used within the four 
papers. For more detailed information and other methods used, please read under 
methods in each paper. 
 
2.2.1 Viability measurements 
 
In these studies, viability was measured by different methods, XTT, Trypan Blue 
exclusion assay and colony formation assay (clonogenic assay).  Using several methods 
are preferable, since it will give more truthful information about the viability of cells 
and specific targets/effects induced by the treatment. 
 
XTT is a yellow colored tetrazolium salt which will shift to orange color when cleaved 
to formazan, by metabolically viable cells, which give information of the functionality 
of mitochondria. Viability of surviving cells after treatment is evaluated by measuring 
the UV absorbance spectrum at 470nm and 650 nm. 
 
Trypan blue exclusion assay is based on addition of diazo dye to cells, which easily 
enters the cell membrane of damaged or dead cells.  Surviving fraction of cells after 
treatment is determined by counting number of viable cells (unstained) and 
damaged/dead cells (stained) using an automatic cell counter (BioRad).  
 
Long term cytotoxic effect was further evaluated by colony formation assay (paper II 
and III). Cells are seeded and treated for 3-8 h, followed by reseeding of cells at low 
density in fresh media and incubation for 9-12 days. Established single cell clones 
(comprising more than 50 cells) are stained and counted for evaluation of clonal growth 
efficiency. 
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 Paper I  
Selenium compounds are substrates for glutaredoxins: a novel pathway for 
selenium metabolism and a potential mechanism for selenium-mediated 
cytotoxicity. 
 
Background 
Selenium compounds are known to selectively mediate cell death in tumor cells, 
presumably via ROS formation and subsequent oxidative stress. Previous studies have 
shown the interaction between the thioredoxin system and selenium compounds, 
resulting in redox cycles with oxygen, and that suppression of TrxR1, increases the 
toxicity of selenite in tumor cells in vitro. Conversely, overexpression of TrxR1 
decreases this toxicity induced by selenium.  
Aim 
In this project we aimed to study the possible interactions between glutaredoxin 1 
(Grx1) and different selenium compounds and the role of Grx1 in selenium induced 
toxicity in tumor cells. 
Result 
In this study we showed that selenite, GS-Se-SG and seleno-DL-cystine were all 
substrates to the glutaredoxin system, in a concentration-dependent manner, in vitro. 
The reduction of selenite and GS-Se-SG were non-stoichiometric, due to formation of 
selenide and following continuous redox cycling with oxygen. Furthermore, selenite 
and GS-Se-SG induced superoxide formation, detected in H157 cells, but not seleno-
DL-cystine. Treatment with selenite induced the mRNA expression of glutaredoxins 
and the amount of active Grx1 protein. Selenite also modulated the intracellular redox 
balance, leading to increased amount of total cysteine, and the protein-bound 
glutathione and cysteine levels. In cell experiments, we also demonstrated that Grx1 
increases the selenium cytotoxicity, using siRNA and transient overexpression of Grx1. 
 
Discussion  
Selenium compounds are known to generate ROS formation and oxidative stress in 
tumors. However, the exact cytotoxic mechanisms are still not fully understood. It is 
known since previously that selenium compounds are reduced by the thioredoxin 
system [40, 301], glutathione and glutathione reductase [42], and free thiols. This study 
provides evidence of the contribution of Grx in selenium metabolism, where we 
demonstrate that selenium compounds are substrates for Grx. Selenite induced both the 
mRNA and protein expression of Grx1 and changed the intracellular redox balance to a 
more oxidized state. We further conclude that high intracellular levels of Grx1, 
contributes to selenium cytotoxicity, proved by transient overexpression of Grx1, 
leading to increased toxicity of selenium compounds, while suppression of Grx1 with 
siRNA, decreased the selenium induced toxicity. This is contrast to previous findings, 
where suppression of TrxR instead enhanced selenium toxicity in lung cancer cells 
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[302]. Our results suggest diverse roles of the thioredoxin and the glutaredoxin systems, 
in terms of selenium mediated toxicity.  
 
Taken together, this study provides information of a novel pathway for selenium 
metabolism and the role of glutaredoxins in selenium cytotoxicity. 
 
2.3.2 Paper II 
 
Methylselenol Formed by Spontaneous Methylation of Selenide Is a Superior 
Selenium Substrate to the Thioredoxin and Glutaredoxin Systems 
 
Background 
From previous studies we know that selenium compounds are substrates to the 
thioredoxin and the glutaredoxin systems. It has also been shown that uptake of 
selenium is increased when the extracellular environment is reduced, related to the 
presence of thiols. Methylated selenium compounds, like methylselenol and 
methylseleninic acid are proposed to be the key metabolites in cancer prevention and 
treatment. Methylselenol is believed to be formed from selenide by methyltransferases, 
from methylselenocysteine by β-lyase cleavage, or from selenomethionine by γ-lyase. 
In cells, methylation reactions are predominantly formed in the presence of s-
adenosylmethionine (SAM) which transfers methylgroups enzymatically in several 
metabolic pathways. SAM is also involved in the formation of glutathione via 
homocysteine.  
Aim 
In this study we aimed to elucidate the possibility of a spontaneous formation of 
methylselenol, from selenide, during reduction of selenite or GS-Se-SG, in the presence 
of SAM. We further aimed to study a possible increased reactivity with the thioredoxin 
and the glutaredoxin system and cytotoxicity in tumor cells.  
Result 
We showed non-enzymatic formation of methylselenol in vitro in the presence of 
SAM. Methylselenol was a better substrate to the thioredoxin and the glutaredoxin 
system in vitro, compared to selenide. We further showed the ability of methylselenol 
to increase the hydroperoxidase activity and to be more efficient in reducing 
cytochrome C, compared with selenide alone. We identified monomethylselenol to be 
the metabolite formed under these conditions, by LDI-MS spectrometry. Treatment of 
lung cancer cells (H157) with selenite and SAM increased the toxicity, and changed the 
morphology of the cells undergoing cell death. This was not caused by increased 
selenium uptake or secretion of thiols, since SAM alone did not change the thiol 
secretion from xCT antiporter. 
 
Discussion 
Methylselenol is considered as the most active anti-cancer metabolite to induce 
apoptosis in cancer cells [48], and to be formed enzymatically by methyltransferases 
[49]. In this study we present novel interactions of selenium compounds and SAM, 
leading to a spontaneous formation of methylselenol. This new finding was proven by a 
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three-fold increase of the reaction rate, while no reaction occurred by SAM in the 
absence of selenium. Monomethylselenol was identified by LDI-MS as the active 
metabolite, although at very low concentrations, due to its unstable and volatile nature. 
Methylated and non-methylated selenium species induce different cell death modes. 
Generally, methylated species are more prone to induce a caspase dependent apoptosis, 
and non-methylated organic selenium species mostly induce a non-caspase dependent 
apoptosis. We found an increased toxicity when treating with cells with selenite and 
selenodiglutathione in combination with SAM. 
 
This new finding of a spontaneous formation of methylselenol is of great importance, 
especially physiologically and pharmacologically, since the cellular concentration of 
SAM is tissue dependent and reported to be increased in tumors [303]. This study may 
provide new information in selenium mediated toxicity in cancer treatment. 
 
2.3.3 Paper III  
 
Selenium induces a multi-target cell death process by complex mechanisms 
beyond ROS formation 
 
Introduction 
Redox active selenium compounds are emerging as promising anti-cancer drug, in sub-
toxic doses. The most accepted mechanism of selenium cytotoxicity is mainly via ROS 
formation. Lately, several reports have described selenium induced programmed cell 
death (PCD). However, these describe no common cell death pathway, and therefore 
this might dependent of both the molecular structure of the selenium compounds and 
used cellular model system. 
Aim 
In this study, we aimed to compare the cell death mechanisms induced by three redox 
active selenium compounds, with different molecular structure (selenite, GS-Se-SG and 
Se-DL-cystine) in one cell-line (HeLa).  
Results 
Both selenite and GS-Se-SG are metabolized to selenide in a reducing extracellular 
environment. However, they displayed striking differences in the molecular targets and 
in time. We found selenite to cause a superoxide induced necroptosis. We discovered 
that GS-Se-SG was able to glutathionylate protein thiols, including cell surface 
structures, with following induced apoptosis. GS-Se-SG also induced superoxide 
formation and DNA strand-break, but differed in time, compared to selenite. Seleno-
DL-cystine induced cell death with two sub-populations. One sub-population exhibited 
typical apoptotic morphology while the other was characterized as paraptosis-like cell 
death, causing massive vacuolation within the cytosol and following ER-stress. 
Discussion 
This study shows the complexity of selenium induced cell death, and the ability of 
these redox active selenium compounds to target multiple cellular compartments in 
cancer cells. The differences between selenite and GS-Se-SG were surprising, since 
both are readily formed to selenide, in a reducing environment. The ability of GS-Se-
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SG to glutathionylate surface proteins and thiols, and a potential activation of death 
receptors, might explain this difference. In particular, receptors belonging to the Fas 
family of are known to be activated by ROS induced- or glutathionlyation induced 
oxidation, leading to extrinsic activated apoptosis [304, 305]. The phenomenon with 
two cell death pathways (both caspase-dependent apoptosis and caspase-independent 
paraptosis, accompanied with autophagy and ER-stress) activated by a single treatment 
has been described recently by others [306, 307]. These dual cell deaths were suggested 
by Li et al. to be activated by p53, and Wang et al. describe the vacuolation and 
paraptosis to be mediated by MAPK pathway. We suggest that this might be cell cycle 
dependent. 
 
Compared with most modern cytostatic drug, which affects mostly single or few 
pathways, this ability of redox active selenium compounds to multi-target tumor cells, 
is of great benefit in cancer treatment and pharmacological aspects that might prevent 
development of drug resistance. Taken together, these results validate the broad 
complexity of redox active selenium compounds to mediate cell death, and for future 
therapeutic research. 
 
2.3.4 Paper IV  
Selenite potentiates all-trans retinoic acid induced maturation of NB-4 cells 
 
Introduction 
Acute myeloid leukemia (AML) is recognized as an increased expansion of malignant 
hematopoietic blast cells which has failed to differentiate into mature leukocytes. Acute 
promyelocytic leukemia (APL) comprises 5-10 % of all cases of AML, and caused by a 
genetic translocation, leading to fusion of the retinoic acid receptor alpha (RARα), and 
promyelocytic leukemia gene (PML). The resulting fusion protein exerts transcriptional 
inhibition of gene expressions, prerequisite for differentiation of immature blast cells. 
APL is treated with all-trans retinoic acid (ATRA) have been successful, but often 
leads to remission and development of resistance against ATRA treatment Treatment 
with arsenic trioxide, which targets thiol residues of zinc-fingers of PML subunit of the 
PML-RARα protein, has been shown to be successful in combination with ATRA in 
treatment of AML-patients and a high complete remission, although, often with serious 
side-effects. 
Aim 
Redox active selenium compounds, like selenite, are known to efficiently oxidize thiols 
residues. This can potentially destabilize zinc-moiety in the zinc-finger proteins. We 
therefore aimed to study the role of selenite in combination with ATRA treatment to 
evaluate any possible differentiating effect of NB4 blast cells.  
Results 
Selenite treatment alone inhibited the viability of the NB4 cells with over 50% after 5 
days, while this was protected in the co-treatment with ATRA. ATRA alone inhibited 
the cellular proliferation, which was even more pronounced in the co-treatment. ATRA 
increased the expression of differentiation marker CD 11b, but not selenite alone. 
However, the combined treatment increased the expression of CD 11b from 29% to 
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41%. Moreover, co-treatment also increased the maturation process into neutrophils in 
terms of morphology. The mRNA expression along with protein expression of redox 
proteins were evaluated after the treatments. Several of these were altered by either 
selenite or ATRA. ATRA alone also down-regulated the expression of xCT protein, 
indicating the possible connection with the redox regulated differentiation mechanism. 
GSK3β, implicated in ATRA-induced differentiation in AML, were down-regulated by 
selenite treatment alone, and remained in the co-treatment with ATRA. Selenite alone 
also down-regulated the PML-RARα protein, which was even more pronounced in the 
combination treatment with ATRA.  
Discussion 
There are increasing evidences of the importance of redox modulation in 
differentiation, and reports of ROS induced differentiation in leukemia cells [75, 76]. A 
previous study with selenite treatment of NB4 cells, showed induced apoptosis, which 
was increased by the addition of ATRA [308]. In this study, we show that combined 
treatment with selenite and ATRA increased the differentiation of NB4 cells into 
neutrophils. This was also evident from morphological evaluation and increased 
expression CD11b. We showed that selenite alone was able to degrade the PML-RARα 
protein, which was persistent in combined treatment with ATRA. This suggests the 
plausible connection with the differentiation effects. ATRA treatment increased the 
expression of Grx1 and Trx2, both on mRNA and protein level.  
 
Taken together, these results indicate a potentiating effect of selenite in combination 
with ATRA treatment in the differentiation of APL. 
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2.4 MAIN CONCLUSIONS FROM THE PAPERS; 
 
Paper I.  
o Glutaredoxins were able to reduce the selenium compounds selenite, 
selenodiglutathione and seleno-DL-cystine, by a mono-thiol mechanism. 
o Overexpression of Grx1 increased the selenium cytotoxicity, while suppression 
of Grx1 decreased the selenium cytotoxic effects.  
o The glutaredoxin system may have an opposite effect in selenium cytotoxicity, 
compared with the thioredoxin system. 
o Glutaredoxins contributes to the selenium metabolism. 
 
Paper II. 
o Methylselenol can be formed spontaneously by selenide and s-
adenosylmethionine (SAM). 
o Methylselenol was a superior substrate to the thioredoxin and the glutaredoxin 
systems, compared to selenide. 
o Co-treatment with SAM and selenite/selenodiglutathione increased the 
cytotoxic effects in H157 cells, not dependent of increased selenium uptake or 
changes of the extracellular redox environment. 
 
Paper III.  
o Redox active selenium compounds induced diverse cell death modes, by mulit-
target mechanisms in HeLa cells. 
o Selenite induced a ROS-dependent necroptosis. 
o Selenodiglutathione was able to glutathionylate protein thiols, including 
organelle membrane structures, which may lead to signaling cascades and 
induce apoptosis. 
o Seleno-DL-cystine induced cell death by two distinct sub-populations, one with 
characteristic apoptosis phenotype, while the other displayed morphology with 
large cytoplasmic vacuoles and no nuclear effect. This was distinguished as a 
paraptotic cell death with following unfolded protein response and ER-stress.  
 
Paper IV. 
o Combining ATRA treatment with selenite, protected against selenite 
toxicity in NB4 cells. 
o Selenite potentiated the effect of ATRA induced differentiation, by 
increased up-regulation of CD11b expression. 
o Selenite was able to degrade the PML-RARα protein, which was even more 
pronounced in combination with ATRA treatment. 
o ATRA increased the expression of Grx1 and Trx2 on mRNA level and 
protein level, and decreased the expression of  xCT. Selenite induced a shift 
in the expression of Grx2 protein isoforms.  
o Maturation of NB4 cells by ATRA and selenite treatment might involve 
redox regulating mechanisms and a shift in the redox balance.  
 36 
 
 
2.5 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
 
A respectful number of studies during the past decades have described the effectiveness 
of various selenium compounds not only as a cancer-preventive compound, but also as 
promising anti-cancer drugs. This dual ability of selenium to fight cancer makes it even 
more interesting. The triggering mechanisms have not been clearly described, apart 
from the induction of reactive oxygen species. The papers within this thesis have all 
been focused on the ability of selenium compounds to induce cell death and the 
mechanisms they trigger within tumors cells.  This has been studied with different 
aspects in each paper.  
 
It has previously been shown that several selenium compounds are reduced by the 
thioredoxin system, glutathione and in the presence of thiols. In paper I, the central 
question was the role of Grx1 in selenium metabolism and cytotoxicity in tumor cells. 
We found selenium compounds to be substrates to glutaredoxins (Grx1 and Grx2), and 
to contribute in the selenium metabolism. Both selenite and selenodiglutathione were 
reduced non-stoichiometrically, due to formation of selenide which redox cycles with 
oxygen and produces superoxide, while Seleno-DL-cystine instead was reduced 
stoichiometrically by Grx1. We detected superoxide formation only in the selenite and 
selenodiglutathione treatments, already here, indicating the differences of seleno-DL-
cystine to induce different mechanisms in terms of cytotoxicity (more thoroughly 
studied in Paper III).  Furthermore, overexpression of Grx1 increased the cytotoxicity 
of the selenium compound. The redox shift induced by selenite within the cells, lead to 
increased glutathionylation of proteins and cysteines. These results were not altered 
when Grx1 was suppressed by siRNA. Why so? Probably because of the co-existence 
of other redox regulating systems and the relatively low level of Grx1 (1 µM) in cells, 
and may not therefore be crucial in this case.  
Future perspectives: These findings and different role of the glutaredoxin system, 
compared with the thioredoxin system, in selenium metabolism, make Grx1 as a very 
interesting marker in tumors. Grx1 would be especially interesting as a predictive 
marker for selenium treatment, when using selenium as a cytostatic agent.   
 
In Paper II, we studied the role of s-adenosylmethionine (SAM), in the presence of 
selenium compounds, and the possibility of a spontaneous methylation of selenide. 
Methylselenol is a selenium intermediate, which is highly reactive, and believed to be 
the most efficient selenium metabolite in treatment of cancer. In the selenium metabolic 
pathway, methylselenol is derived from selenometionine by γ-lyase cleavage or from 
selenomethylselenocysteine by a β-lyase cleavage. SAM is a naturally occurring methyl 
donor and able to methylate many substrates in different metabolic pathways, 
predominantly in the presence of methyl transferases. SAM has been shown to 
spontaneously methylate proteins, DNA and lipids.  SAM is a precursor to 
homocysteine and a part of the trans-sulfuration pathway, which regulates the 
glutathione synthesis. We showed that methylselenol can be spontaneously formed by 
selenide, in the presence of SAM. This spontaneously formed methylselenol were more 
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cytotoxic compared to the selenium compounds when treating tumor cells, which was 
not dependent of oxidation state of the microenvironment, or an increased uptake. 
Interestingly, even though thiol secretion was blocked, treatment with selenite and 
SAM resulted in selenium uptake, but at later time point (8-24 h). This indicates that 
extracellularily spontaneously formed methylselenol, still have the ability to enter 
resistant tumor cells. However, seleno-DL-cystine again, did not show the same pattern 
and did not react with SAM in vitro. 
Future perspectives: Taken together, these findings are interesting and open for new 
treatment possibilities and new information of the selenium metabolism, and especially 
of interest to highly metabolic organs. Since this study was performed in a non-small 
lung cancer cell line (H157) as a model-system, it would be very interesting to study 
selenium cytotoxicity in liver, kidney and pancreatic tumor cells, from the aspect of 
selenium interaction with SAM, and formation of methylated selenium species. The 
liver and pancreas contains higher basal level of SAM, meaning that a more efficient 
selenium treatment might be achieved when treating tumors within these organs. In 
would also be valuable to study the uptake mechanisms of methylated species, since 
they seems not to totally depend on the presence of thiols. Due to a higher expression 
of cystathione β-lyase within the liver, it would be beneficial to use organic selenium 
compounds like selenomethylselenocysteine (SeMCS).  
 
Studies of cell death mechanisms in tumors can be quite complex and difficult to 
determine, depending on both genetically variations and their specific expression 
pattern. It is also very tempting (and fascinating!) to study selenium induced cell death 
mechanisms, due to the amount of reports of varied results and conclusions. Apart from 
this, it is of great importance to distinguish the intracellular mechanisms and the 
intracellular targets that selenium compounds induce, in order to predict which 
selenium compound that might be most beneficial to use in cancer treatment, but it may 
also give some information of the mechanisms of possible toxic side effects. In Paper 
III, we methodically studied the underlying cell death mechanisms induced by selenite, 
selenodiglutathione and seleno-DL-cystine, looking at mRNA levels, protein 
expression, superoxide production, but also mitochondrial- and DNA-effects, and 
changes of morphology, in time and in one cell line (HeLa). We concluded that these 
selenium compounds induced cell death differently, especially seleno-DL-cystine, as 
noted in our previous studies. Also, the mRNA data from the 24 h time-point, verified 
that these selenium compounds affected the mRNA expression differently. Selenite 
induced necroptosis, determined by high ROS production and DNA damage, and 
cleavage of PARP-1, which was partly prevented by necrostatin-1. The most 
pronounced early effect by selenite where on the mitochondrial DNA, which was not 
protected by necrostatin-1.  
 
An important finding was the ability of selenodiglutathione to glutathionylate thiols, 
which might be the reason to the differences compared to selenite, since both selenite 
and selenodiglutahione are reduced to selenide. Selenodiglutathione requires only two 
electrons to be reduced to selenide, compared with selenite, which requires four. In 
addition, selenodiglutathione can also form selenopersulphide (GS-Se-H) by one 
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electron. Selenopersulphide (GS-Se-H) is a very reactive intermediate and may also 
react with thiols of proteins, including important receptor proteins within the cell 
surface and activate signaling cascades and the extrinsic apoptosis pathway. This means 
that selenodiglutathione (GS-Se-SG) has higher potential as an oxidizing agent by 
forming; HSe-, GS-Se- + GS-H/GS-R. Seleno-DL-cystine induced two distinct cell 
death pathways, one with typical apoptosis-like morphology, and one paraptosis-like 
cell death, with massive vacuolation of the cytoplasm and induced ER-stress. We 
suggest that this might also be cell cycle dependent, which should be studied in more 
detail in the future. 
 
Future perspectives: S-glutathionylation processes regulate many pathways, and also 
an important event in regulation of apoptosis and activation of death receptors. Among 
these are s-glutathionylation of Fas  (CD95) upon activation by FasL, which is 
sustained and further increased after Grx1-degradation by caspase 3 [304]. It would 
therefore be very interesting to study the role of selenodiglutathione in more detail on 
cell surface receptors, using specific inhibitors and specify this mechanism in more 
detail.  
 
A growing number of evidences point at that redox regulation is implicated in 
differentiation of un-matured cells. It has further been proposed that ROS also 
regulated the self-renewal process of hematopoietic stem cell, and the reason for the 
existing low ROS levels and hypoxia in stem cells are to prevent against DNA damages 
of the genome [309]. Due to their long life span, they may therefore be more sensitive 
to ROS accumulation and/or gain of DNA mutations leading to malignancies, like 
leukemia. In Paper IV, we studied the role of selenite and retinoic acid (ATRA) to 
induce differentiation of promyelocytic leukemia, using NB4 cells. The experiment was 
followed during 5 days and evaluated by mRNA and protein expression along with 
expression of CD-markers related to differentiation and morphological studies 
including the nuclei. Selenite alone did not induce signs of differentiation, but increased 
the differentiating effect of ATRA, determined by the increased expression of CD11b 
and the morphological evaluation of the changed shape of the nuclei, indicating a 
maturation of the blast cells into neutrophils. Selenite treatment alone decreased the 
expression of PML-RARα, which is evidence of an initiated differentiation process. 
Both selenite and ATRA separately affected the expression of redox proteins, which 
further strengthen an ongoing redox regulated process.  
 
Future perspectives: We might have gained more powerful evidences of an initiated 
differentiation process by running the experiment 3-5 days longer, but the problematic 
thing with running experiment for this long, is the increased cell density and nutrition 
supply. We tried to overcome this by a low seeding density (25 000 cell/ml) and by 
exchange of media and re-treatment at day 3. We have shown for the first time that 
selenite is able to down-regulate PML-RARα, which is an interesting finding from the 
therapeutic perspective. Since PML-RARα is associated with transcriptional 
suppression of neutrophilic differentiation associated genes, this study provide 
promising findings for further investigation. The future work will aim at understanding 
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the differences in the nutrophilic differentiation associated gene expression between 
selenite and combined treatment, to clarify the role of selenite in this process. To do so, 
we are currently investigating the functionalities of several transcription factors 
important for the differentiation of myeloid progenitors. In addition, a similar treatment 
will be tested on primary cells form patients, as the next step. 
 
In summary; Redox active selenium compounds are promisingly potent anti-cancer 
drugs. The cytotoxic mechanisms induced by selenium compounds include reduction to 
selenide partly regulated by the thioredoxin and the glutaredoxin systems. Selenium 
compounds can be spontaneously methylated by s-adenosylmethionine to 
methylselenol.  Selenium compounds do not targets a single, but multiple pathways and 
activates cell death differently, depending of their molecular structure. Redox active 
selenium compounds have therefore a higher potency in treatment of tumor cells, which 
is of benefit against the development of drug resistance in tumors. Selenite may also 
potentiate the effect of ATRA to induce differentiation in treatment of APL. 
 
Moving forward in selenium research and clinical trials, growing evidences points to 
the use of different selenium compounds, depending of the tissue where the tumors are 
localized or originated from. It might also be beneficial to use selenium before or after 
or combined with cytostatic drugs.  This is of cause important to study in vitro.  
Due to some reports of a minor risk for diabetes type 2, it might be important to 
evaluate the basal level of selenium in patients, before treatment with selenium.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Personally; 
I myself have become a believer of “selenium power” during my study time, and I am 
so grateful to have the opportunity to continue to work in the selenium field.  
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